PARP mediated DNA damage response, genomic stability and immune responses

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Poly(ADP-ribose) polymerase (PARP) enzymes, particularly PARP1, are crucial for DNA damage response and genome stability.
• PARP inhibitors (PARPis) are established synthetic lethal therapies for BRCA-deficient tumors, primarily through catalytic inhibition and PARP-DNA trapping.

Purpose of the Study:

• To explore the role of PARP1 in tumor immune modulation.
• To evaluate the potential of combining PARPis with immunomodulators for enhanced anti-tumor effects.

Main Methods:

• Investigated the molecular mechanisms by which PARP1 blockade influences innate immunity.
• Assessed the combined efficacy of PARPis and immune agents in preclinical tumor models.

Main Results:

• PARP1 blockade was found to induce innate immune responses via specific molecular pathways.
• Combined PARPis and immunomodulators demonstrated synergistic effects in inhibiting tumor growth and overcoming immune escape.

Conclusions:

• PARP1 plays a significant role in regulating the tumor immune microenvironment.
• Combining PARPis with immunotherapies presents a promising strategy for more effective cancer treatment by enhancing anti-tumor immunity and blocking immune evasion.